1. Vaish, Vivek, Kim, Joohwee, Shim, Minsub. 2017. Jagged-2 (JAG2) enhances tumorigenicity and chemoresistance of colorectal cancer cells. In Oncotarget, 8, 53262-53275. doi:10.18632/oncotarget.18391. https://pubmed.ncbi.nlm.nih.gov/28881809/
2. Chen, Wujun, Wu, Xiaolin, Hu, Jianxia, Wang, Jie, Xing, Dongming. 2024. The translational potential of miR-26 in atherosclerosis and development of agents for its target genes ACC1/2, COL1A1, CPT1A, FBP1, DGAT2, and SMAD7. In Cardiovascular diabetology, 23, 21. doi:10.1186/s12933-024-02119-z. https://pubmed.ncbi.nlm.nih.gov/38195542/
3. Coppens, Sandra, Barnard, Alison M, Puusepp, Sanna, Walter, Glenn A, Kang, Peter B. 2021. A form of muscular dystrophy associated with pathogenic variants in JAG2. In American journal of human genetics, 108, 840-856. doi:10.1016/j.ajhg.2021.03.020. https://pubmed.ncbi.nlm.nih.gov/33861953/
4. Pietras, Alexander, von Stedingk, Kristoffer, Lindgren, David, Påhlman, Sven, Axelson, Håkan. 2011. JAG2 induction in hypoxic tumor cells alters Notch signaling and enhances endothelial cell tube formation. In Molecular cancer research : MCR, 9, 626-36. doi:10.1158/1541-7786.MCR-10-0508. https://pubmed.ncbi.nlm.nih.gov/21402725/
5. Platonova, Natalia, Lazzari, Elisa, Colombo, Michela, Jamieson, Catriona H M, Chiaramonte, Raffaella. 2023. The Potential of JAG Ligands as Therapeutic Targets and Predictive Biomarkers in Multiple Myeloma. In International journal of molecular sciences, 24, . doi:10.3390/ijms241914558. https://pubmed.ncbi.nlm.nih.gov/37834003/
6. Yustein, Jason T, Liu, Yen-Chun, Gao, Ping, Bergsagel, P Leif, Dang, Chi V. 2010. Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model. In Proceedings of the National Academy of Sciences of the United States of America, 107, 3534-9. doi:10.1073/pnas.0901230107. https://pubmed.ncbi.nlm.nih.gov/20133585/
智鼠故事 
